Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD – Get Free Report) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 467,461 shares, a growth of 161.0% from the July 15th total of 179,105 shares. Based on an average daily volume of 2,318,553 shares, the short-interest ratio is currently 0.2 days. Currently, 4.2% of the company’s stock are sold short.
Hong Kong Pharma Digital Technology Price Performance
Shares of Hong Kong Pharma Digital Technology stock opened at $0.42 on Friday. The company’s 50-day moving average price is $0.41 and its 200-day moving average price is $0.57. Hong Kong Pharma Digital Technology has a 12-month low of $0.31 and a 12-month high of $2.58.
Hong Kong Pharma Digital Technology (NASDAQ:HKPD – Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $3.15 million for the quarter.
Institutional Trading of Hong Kong Pharma Digital Technology
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.
View Our Latest Report on HKPD
Hong Kong Pharma Digital Technology Company Profile
Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.
Further Reading
- Five stocks we like better than Hong Kong Pharma Digital Technology
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Hong Kong Pharma Digital Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hong Kong Pharma Digital Technology and related companies with MarketBeat.com's FREE daily email newsletter.
